Published on December 18, 2009 at 9:22 AM
PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com),
an emerging biotechnology company developing acute care products for
infectious diseases and acute cardiovascular disorders, has successfully
completed the first two segments of a Phase 1B clinical safety study
with its novel antibiotic drug candidate PMX-30063. We believe PMX-30063
is the first and only small-molecule mimetic of host defense proteins in
clinical development intended for systemic administration, with a novel
mechanism of action distinct from other antibiotic drugs and believed to
make bacterial resistance unlikely to develop. The data from the study
demonstrate that administration of multiple doses of PMX-30063 at
varying levels are safe and well-tolerated. The doses and blood levels
of drug achieved in this study suggest that a beneficial therapy may
exist. Further clinical development is planned to continue for the
initial indication for this drug as a broad treatment for Staphylococcus
infections.
Source PolyMedix, Inc.